Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report.
BACKGROUND
This study reports a case of bevacizumab administered to treat choroidal neovascularisation in a woman later discovered to be pregnant.


METHODS
A 25-year-old pregnant woman developed myopic choroidal neovascularisation in both eyes.


METHODS
Both eyes were treated with a total of 3 intravitreal injections of bevacizumab sequentially.


RESULTS
Vision improved significantly in both eyes. There were no evident pregnancy-related complications at 1 year postpartum.


CONCLUSIONS
Although anti-vascular endothelial growth factor (VEGF) therapy did not result in any detectable short-term adverse event in this mother and baby, the potential toxicity of these agents must be carefully considered in pregnant patients.
Center for Advanced Eye Care, Carson City, NV 89703, USA. ziqiangw@hotmail.com
Ziqiang
Z
Wu
Jingjing
J
Huang
Srinivas
S
Sadda
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab